{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T21:59:27Z","timestamp":1698357567482},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1991,1,1]],"date-time":"1991-01-01T00:00:00Z","timestamp":662688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1991]]},"DOI":"10.1007\/bf00626369","type":"journal-article","created":{"date-parts":[[2004,11,26]],"date-time":"2004-11-26T05:14:48Z","timestamp":1101446088000},"page":"459-462","source":"Crossref","is-referenced-by-count":6,"title":["Effect of duration of levodopa\/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease"],"prefix":"10.1007","volume":"41","author":[{"given":"S. G.","family":"Bowes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J. A.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. W.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Leeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Dobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Dobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ana.410040619","volume":"4","author":"L Direnfeld","year":"1978","unstructured":"Direnfeld L, Spero L, Marotha J, Seeman P (1978) The L-dopa ?on-off? effect in Parkinson's disease: treatment by transient drug withdrawal and dopamine receptor resensitization. Ann Neurol 4: 573?575","journal-title":"Ann Neurol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00561903","volume":"17","author":"MA Evans","year":"1980","unstructured":"Evans MA, Triggs EJ, Broe GA, Saines N (1980) Systemic availability of orally administered L-dopa in the elderly Parkinsonian patient. Eur J Clin Pharmacol 17: 215?221","journal-title":"Eur J Clin Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1212\/WNL.31.10.1288","volume":"31","author":"MA Evans","year":"1981","unstructured":"Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Pacell PD (1981) Gastric emptying rate and systemic availability of levodopa in the elderly Parkinsonian patient. Neurology 31: 1288?1294","journal-title":"Neurology"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.1990.tb03617.x","volume":"29","author":"JR Hughes","year":"1990","unstructured":"Hughes JR, Bowes SG, Leeman AL, O'Neill CJA, Deshmukh AA, Nicholson PW, Dobbs SM, Dobbs RJ (1990) Parkinsonian abnormality of foot strike: a phenomenon of ageing and\/or one responsive to levodopa therapy? Br J Clin Pharmacol 29: 179?186","journal-title":"Br J Clin Pharmacol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/jnnp.52.6.718","volume":"52","author":"PA Kempster","year":"1989","unstructured":"Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiat 52: 718?723","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/cpt1971124678","volume":"12","author":"I Kuruma","year":"1971","unstructured":"Kuruma I, Bartholini G, Tissot R, Pletscher A (1971) The metabolism of L-3-0-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 12: 678?682","journal-title":"Clin Pharmacol Ther"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/273059a0","volume":"273","author":"T Lee","year":"1978","unstructured":"Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis of dopaminergic supersensitivity in Parkinson's disease. Nature 273: 59?61","journal-title":"Nature"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-3-642-73899-9_13","volume-title":"Drugs for the treatment of Parkinson's disease","author":"PA Lewitt","year":"1989","unstructured":"Lewitt PA (1989) The pharmacology of levodopa in treatment of Parkinson's disease: An update. In: Calne DB (ed) Drugs for the treatment of Parkinson's disease. Springer, New York, pp 325?384"},{"key":"CR9","first-page":"389","volume":"47","author":"MD Meunter","year":"1972","unstructured":"Meunter MD, Sharpless NS, Tyce GM (1972) Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. Mayo Clinic Proc 47: 389?395","journal-title":"Mayo Clinic Proc"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/bmj.293.6543.379","volume":"293","author":"NP Quinn","year":"1986","unstructured":"Quinn NP, Hussain FA (1986) Parkinson's disease. Br med J 293: 379?382","journal-title":"Br med J"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/archneur.1977.00500160042007","volume":"34","author":"L Rivera-Calimlim","year":"1977","unstructured":"Rivera-Calimlim L, Tandon D, Anderson F, Joynt R (1977) The clinical picture and plasma levodopa metabolite profile of Parkinsonian non-responders. Treatment with levodopa and decarboxylase inhibitor. Arch Neurol 34: 228?232","journal-title":"Arch Neurol"},{"key":"CR12","unstructured":"Robertson DRC, Higginson I, Macklin BS, Waller DG, Renwick AG (1990b) The influence of protein on the absorption of levodopa. Br J Clin Pharmacol 29: 608P"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2125.1990.tb03601.x","volume":"29","author":"DRC Robertson","year":"1990","unstructured":"Robertson DRC, Renwick AG, Wood ND, Cross N, Macklin BS, Fleming JS, Waller DG, George CF (1990a) The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 29: 47?53","journal-title":"Br J Clin Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.1989.tb03506.x","volume":"28","author":"DRC Robertson","year":"1989","unstructured":"Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28: 61?69","journal-title":"Br J Clin Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/242463a0","volume":"242","author":"DN Wade","year":"1973","unstructured":"Wade DN, Mearrick PT, Morris JL (1973) Active transport of L-dopa in the intestine. Nature 242: 463?465","journal-title":"Nature"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1471-4159.1975.tb04415.x","volume":"25","author":"LA Wade","year":"1975","unstructured":"Wade LA, Katzman R (1975) Synthetic amino acids and the nature of L-dopa transport at the blood-brain barrier. J Neurochem 25: 837?842","journal-title":"J Neurochem"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1212\/WNL.30.12.1257","volume":"30","author":"WJ Weiner","year":"1980","unstructured":"Weiner WJ, Koller WC, Perlik S, Nausieda PA, Klawans HL (1980) Drug holiday and management of Parkinson's disease. Neurology 30: 1257?1261","journal-title":"Neurology"},{"key":"CR18","series-title":"Progress in Neurology series","first-page":"233","volume-title":"Research progress in Parkinson's disease","author":"MD Yahr","year":"1981","unstructured":"Yahr MD (1981) Pharmacological treatment of Parkinson's disease in early and late phases. In: Rose FC, Capildeo R (eds) Research progress in Parkinson's disease. Pitman Medical, London (Progress in Neurology series) pp 233?240"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00626369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00626369\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00626369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:07:44Z","timestamp":1554836864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00626369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1991]]}},"alternative-id":["BF00626369"],"URL":"https:\/\/doi.org\/10.1007\/bf00626369","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991]]}}}